Pharma

Five things for pharma marketers to know: Wednesday, March 22, 2017

Five things for pharma marketers to know: Wednesday, March 22, 2017

By

Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD

 MM&M Startup Showdown connects startups with biopharma execs

MM&M Startup Showdown connects startups with biopharma execs

By

This program is designed to enable entrepreneurs and biopharma marketers to engage in an intelligent way to explore beyond-the-pill partnerships.

What five different pharma marketing careers look like

What five different pharma marketing careers look like

Five highly placed insiders in a range of roles and therapeutic categories share secrets to their success and advice that served them well along the way.

Saturday at SXSW: Hooray for health

Saturday at SXSW: Hooray for health

By

The first days at SXSW Health went deep on entrepreneurship and the marketing thereof.

MM&M conference to explore beyond-the-pill

MM&M conference to explore beyond-the-pill

By

The MM&M Transforming Healthcare Conference will be held May 1 in New York City.

Havas combines Havas Health, Havas consumer health practices into new entity

Havas combines Havas Health, Havas consumer health practices into new entity

By

The organization is now called Havas Health & You and continues to be led by Donna Murphy.

Five things for pharma marketers to know: Monday, March 6, 2017

Five things for pharma marketers to know: Monday, March 6, 2017

By

Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema

Five things for pharma marketers to know: Thursday, March 2, 2017

Five things for pharma marketers to know: Thursday, March 2, 2017

By

Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project

Another Pharmageddon? The Looming Threat to 2017 Ad Budgets

Another Pharmageddon? The Looming Threat to 2017 Ad Budgets

By

Despite budgets bouncing back from a decrease in 2015, big threats have appeared that may temper future plans, Iskowitz writes.

MM&M's top 5 stories in February 2017

MM&M's top 5 stories in February 2017

By

WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram

Five things for pharma marketers to know: Tuesday, February 28, 2017

Five things for pharma marketers to know: Tuesday, February 28, 2017

By

J&J discloses list prices for its drugs; Kite's CAR-T therapy meets study goals; healthcare providers seek to engage patients in decisionmaking

What uncertainty? 72% of health marketers say 2017 budgets are up

What uncertainty? 72% of health marketers say 2017 budgets are up

By

This according to the 172 healthcare marketing executives who participated in the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.

Guidemark Health's Sophy Regelous on why small budgets are increasing

Guidemark Health's Sophy Regelous on why small budgets are increasing

By

Guidemark Health COO Sophy Regelous shares her perspective on the 2017 MM&M/Guidemark Health Healthcare Marketers Report.

Is the Trump Administration the Cure the FDA Needs?

Is the Trump Administration the Cure the FDA Needs?

Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.

MAHF honors Abbate and Lazur, Future Famers

MAHF honors Abbate and Lazur, Future Famers

By

The Medical Advertising Hall of Fame recognized dozens of industry leaders and rising agency executives.

Why Pharma Refuses to See Value in 'Influence'

Why Pharma Refuses to See Value in 'Influence'

At the very least, pharma marketers need to make sure they know the difference between search engine marketing and search engine optimization.

Industry hires and promotions: February 2017

Industry hires and promotions: February 2017

By

Novo Nordisk appoints new CEO, and more people moves for you to know about

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

By

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

By

Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.

Five things for pharma marketers to know: Tuesday, February 7, 2017

Five things for pharma marketers to know: Tuesday, February 7, 2017

By

Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer

Genentech Should Let Us See Its Herceptin Documentary

Genentech Should Let Us See Its Herceptin Documentary

By

The 2009 documentary offers a wealth of detail. Which is why it makes no sense that Genentech doesn't want you to see the damn thing.

10 ways healthcare companies are testing Instagram

10 ways healthcare companies are testing Instagram

By

Pharmaceutical and healthcare companies use a mix of corporate and brand accounts on Instagram, and some are turning to celebrity influencers.

How can drugmakers tell better stories? Try Instagram

How can drugmakers tell better stories? Try Instagram

By

The Kim Kardashian debacle aside, what makes the platform so potentially valuable to pharma and healthcare marketers is its visual story-telling capability.

WPP to merge Ogilvy CommonHealth, ghg, Sudler, and CMI into new company

WPP to merge Ogilvy CommonHealth, ghg, Sudler, and CMI into new company

By By

A WPP insider has been tapped as CEO of WPP Health & Wellness, and Ogilvy CommonHealth chairman/CEO Matt Giegerich is stepping down.

MM&M's top 5 stories in January 2017

MM&M's top 5 stories in January 2017

By

Merck and Aetna partner in value-based drug pricing; data scientists rising in the biopharma ranks; Japanese pharma leads digital health innovation

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

By

The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.

Infographic: How Trump will affect healthcare marketing budgets

Infographic: How Trump will affect healthcare marketing budgets

A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.

Five things for pharma marketers to know: Thursday, January 26, 2017

Five things for pharma marketers to know: Thursday, January 26, 2017

By

J&J to buy Actelion for $30 billion; Pfizer fights advertising ban related to Advil; almost half of women with breast cancer report severe side effects

Five things for pharma marketers to know: Wednesday, January 25, 2017

Five things for pharma marketers to know: Wednesday, January 25, 2017

By

Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims

Ryan Abbate, 2017 MAHF inductee, sets the record straight

Ryan Abbate, 2017 MAHF inductee, sets the record straight

By

The founder of Pacific Communications shares the details of his career as he is inducted into the Medical Advertising Hall of Fame.

OPINION

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

Newsletters